Median suPAR level (ng/mL) for various comorbidities
| All | Survived* | Died* | ||||||
|---|---|---|---|---|---|---|---|---|
| Comorbidity group† | n (%)‡ | Median (IQR) | p Value§ | n (%)¶ | Median (IQR) | n (%)¶ | Median (IQR) | p Value** |
| Charlson score 0 | 3177 (73.2) | 2.9 (2.1–4.2) | 3079 (96.9) | 2.9 (2.1–4.1) | 98 (3.1) | 6.7 (4.6–9.4) | <0.0001 | |
| Cancer | 109 (2.5) | 5.2 (4.0–8.3) | <0.0001 | 74 (67.9) | 5.0 (3.9–6.7) | 35 (32.1) | 7.4 (4.6–12.1) | 0.003 |
| COPD | 471 (10.8) | 3.7 (2.8–5.4) | <0.0001 | 433 (91.9) | 3.6 (2.7–5.1) | 38 (8.1) | 6.3 (3.8–9.5) | <0.0001 |
| CVD | 342 (7.9) | 4.3 (3.0–5.9) | <0.0001 | 303 (88.6) | 4.2 (2.8–5.5) | 39 (11.4) | 6.4 (3.8–8.7) | <0.0001 |
| Dementia | 45 (1.0) | 4.5 (3.5–5.5) | <0.0001 | 35 (77.8) | 4.5 (3.3–5.5) | 10 (22.2) | 4.9 (4.1–8.4) | 0.08 |
| Diabetes | 285 (6.6) | 4.3 (3.0–6.6) | <0.0001 | 266 (93.3) | 4.2 (2.9–6.5) | 19 (6.7) | 6.7 (5.6–9.0) | 0.0003 |
| HIV/AIDS | 2 (0.05) | 8.2 (5.4–10.9) | – | 2 (100.0) | 8.2 (5.4–10.9) | 0 (0) | – | – |
| Liver disease | 40 (0.9) | 7.7 (5.6–11.5) | <0.0001 | 34 (85.0) | 7.3 (5.2–11.1) | 6 (15.0) | 8.9 (7.4–18.7) | 0.16 |
| Paraplegia and hemiplegia | 8 (0.2) | 4.9 (3.4–6.6) | 0.01 | 7 (87.5) | 4.8 (2.9–6.2) | 1 (12.5) | 7.0 (7.0–7.0) | 0.12 |
| Peptic ulcer disease | 19 (0.4) | 4.7 (3.6–8.2) | <0.0001 | 15 (79.0) | 4.6 (3.6–6.5) | 4 (21.1) | 10.7 (5.4–17.4) | 0.18 |
| Renal disease | 42 (1.0) | 9.3 (6.4–12.3) | <0.0001 | 36 (85.7) | 8.0 (6.0–11.0) | 6 (14.3) | 17.3 (13.7–19.7) | 0.002 |
| Rheumatic disease | 12 (0.3) | 6.4 (5.7–9.4) | <0.0001 | 12 (100.0) | 6.4 (5.7–9.4) | 0 (0) | – | – |
*Data on survival and death within 30 days follow-up.
†The 17 original Charlson groups were collapsed into 10 groups, generating the following groups cardiovascular disease (Charlson groups 1–4), liver disease (Charlson groups 9 and 15), diabetes (Charlson groups 10 and 11) and cancer (Charlson groups 14 and 16). The Charlson groups 5 (dementia), 6 (chronic pulmonary disease), 7 (rheumatic disease), 8 (peptic ulcer disease), 12 (paraplegia and hemiplegia), 13 (renal disease) and 17 (HIV/AIDS) remained the same. It should be noted that a patient can be in more than one comorbidity group.
‡Percentage of total cohort.
§Compared with patients with Charlson score 0.
¶Percentage of comorbidity group.
**Compared with survivors in same comorbidity group.
CVD, cardiovascular disease; COPD, chronic obstructive pulmonary disease; suPAR, soluble urokinase plasminogen activator receptor.